Finding that a lower court went too far with an injunction that ignores the Hatch-Waxman safe harbor protections for drug development, the U.S. Court of Appeals for the Federal Circuit handed Avadel CNS Pharmaceuticals LLC a win of sorts.
Teijin Pharma Ltd. has identified crystalline forms of oxazepine derivatives acting as orexin OX2 receptor agonists reported to be useful for the treatment of narcolepsy, hypersomnia and sleep apnea.
Suven Life Sciences Ltd. has synthesized muscarinic M4 receptor positive allosteric modulators (PAMs) reported to be useful for the treatment of pain, psychiatric disorders and neurological disorders.
Individuals with cystic fibrosis show a notably higher rate of attention deficit hyperactivity disorder (ADHD) symptoms than the general population. This association points to a possible role of the cystic fibrosis transmembrane conductance regulator (CFTR) gene, whose mutations cause cystic fibrosis, in the development of ADHD.
Ahead Therapeutics SL has received positive feedback from the EMA on its way toward initiating regulatory toxicology studies for its lead program in myasthenia gravis. The feedback supports the company’s scientific approach.
The recent 510(k) clearance by the U.S. FDA for a core part of Precision Neuroscience Corp. brain-computer interface technology is certainly a boon for the company, and others developing the devices. For the millions of people suffering from health disorders, such as motor neuron disease, spinal cord injury or severe stroke, its sign that a solution which could transform their lives could be just a few years away.
Tenvie Therapeutics Inc. has described endosomal/lysosomal proton channel TMEM175 modulators reported to be useful for the treatment of cancer, neurological disorders, lysosomal storage disorders and inflammatory disorders.
Stroke accounts for nearly 12% of all deaths worldwide, making it the second leading cause of death. In acute ischemic stroke, the ischemia and subsequent return of blood flow create oxidative and nitrosative stress that can overwhelm neurons and disable important circuitry.
Armatus Bio Inc.’s development of ARM-201, an AAV-delivered microRNA therapy for facioscapulohumeral muscular dystrophy (FSHD), has been boosted by a $3 million investment by Solve FSHD.
RSS
